BIA
TBPH icon

Bell Investment Advisors’s Theravance Biopharma TBPH Stock Holding History

Bell Investment Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed -$1K – 2028
2022
Q3 		$1K Buy
+50
New +$469 ﹤0.01% 1586

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bell Investment Advisors's TBPH Position: Q4 2022 in Review

Bell Investment Advisors sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 50 shares — an estimated $1K sold.

Bell Investment Advisors first reported a position in TBPH in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

  • Bell Investment Advisors reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
  • Bell Investment Advisors sold 50 Theravance Biopharma shares in Q4 2022, an estimated $1K.
  • Bell Investment Advisors first reported a position in Theravance Biopharma in Q3 2022 and held it in 1 quarter.
  • Bell Investment Advisors's Theravance Biopharma position peaked at $1K in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Bell Investment Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.